We claim:

1. A process for preparation of pharmaceutical composition of rabeprazole and its salts thereof, with a shelf life of atleast 6 months, comprising steps of

    a. Solubilization of rabeprazole in a solvent

    b. Dissolution of lactose or galactose or trehalose or their combination with or without other excipients under stirring

    c. Adjusting pH to 8.0-11.0

    d. Optionally removing any particulates from the solution

    e. Lyophilization of the solution in an appropriate container

2. The solvent as claimed in claim 1 is water.
3. The solution as claimed in claim 1 contains atleast 2 parts of lactose or galactose or trehalose or their combination for one part of rabeprazole.
4. Removal of particulate matter as claimed in claim 1 is by filtration.
5. Lyophilization as claimed in claim 1, comprises primary drying at product temperature below -10°C and secondary drying at temperature below 25°C.
6. A stable lyophilized pharmaceutical composition of rabeprazole and/or its salts, comprising the rabeprazole in the range of 1% to 40% by weight, lactose or galactose or trehalose or their combination in the range of 55% to 99% by weight and other excipients in the concentration of 0% to 3% by weight.
7. A stable lyophilized pharmaceutical composition of rabeprazole and/or its salts as claimed in claim 6, wherein the rabeprazole is preferably in the concentration of 1% to 30% by weight, lactose or galactose or trehalose or their combination is preferably in the concentration of 65% to 99% by weight and other excipients preferably in the concentration of 0% to 3% by weight.

8. The other excipients as claimed in claim1, are selected from phosphate buffer, carbonate buffer, tonicity agents and antioxidants.

9. A stable lyophilized pharmaceutical composition as claimed in claim 6, which is extemporaneously dissolved in water before administration.